We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

NeoPharm Will Not Face SEC Charges

Law360 (December 1, 2006, 12:00 AM EST) -- Biotech drug maker NeoPharm Inc. announced Friday that the U.S. Securities and Exchange Commission has ended its probe of the company and will not recommend any enforcement action.

The SEC’s formal investigation, which began in March 2004, concerned allegedly misleading public statements the company made regarding the development of its liposome-encapsulated paclitaxel and liposome-encapsulated doxorubicin products, NeoPharm said.

As a result of the alleged misleading statements, a class action lawsuit was filed against the company at about that time.

Additionally, Waukegan, Ill.-based NeoPharm had sued Pharmacia...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.